Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

57.71
+10.9223.34%
Post-market: 57.31-0.4050-0.70%19:59 EST
Volume:7.07M
Turnover:395.13M
Market Cap:7.84B
PE:-4.73K
High:59.15
Open:47.39
Low:45.09
Close:46.79
52wk High:59.15
52wk Low:9.57
Shares:135.81M
Float Shares:118.91M
Volume Ratio:2.06
T/O Rate:5.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0122
EPS(LYR):-0.0122
ROE:8.67%
ROA:4.87%
PB:16.82
PE(LYR):-4,733.04

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
Arrowhead Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
609
Office Location:
177 East Colorado Boulevard,Suite 700,Pasadena,California,United States
Website:
http://www.arrowheadpharma.com
Zip Code:
91105
Phone:
626 304 3400
Fax:
626 304 3401
Introduction:
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Directors

Name
Position
Christopher Anzalone
Chief Executive Officer, President and Director, Chairman of the Board
Adeoye Olukotun
Independent Director
Hongbo Lu
Independent Director
Mauro Ferrari
Independent Director
Michael S. Perry
Independent Director
Victoria Vakiener
Independent Director
William Waddill
Lead Independent Director
Douglass Ingram
Director

Shareholders

Name
Position
Christopher Anzalone
Chief Executive Officer, President and Director, Chairman of the Board
Patrick O'Brien
Chief Operating Officer and General Counsel
Kenneth A. Myszkowski
Chief Financial Officer
James Hamilton
Chief of Discovery and Translational Medicine